Optimal Asset Management Inc. Purchases 7,547 Shares of ABIOMED, Inc. (NASDAQ:ABMD)
Optimal Asset Management Inc. lifted its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 203.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,253 shares of the medical equipment provider’s stock after purchasing an additional 7,547 shares during the quarter. Optimal Asset Management Inc.’s holdings in ABIOMED were worth $1,633,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently made changes to their positions in the company. Synovus Financial Corp increased its stake in ABIOMED by 60.6% during the 1st quarter. Synovus Financial Corp now owns 212 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 80 shares during the period. Sugarloaf Wealth Management LLC boosted its stake in shares of ABIOMED by 100.0% in the 1st quarter. Sugarloaf Wealth Management LLC now owns 250 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 125 shares during the last quarter. Bainco International Investors bought a new position in shares of ABIOMED in the 1st quarter valued at about $39,000. Quadrant Capital Group LLC boosted its stake in shares of ABIOMED by 107.1% in the 4th quarter. Quadrant Capital Group LLC now owns 261 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 135 shares during the last quarter. Finally, Royal Fund Management LLC bought a new position in shares of ABIOMED in the 1st quarter valued at about $68,000. Institutional investors and hedge funds own 94.41% of the company’s stock.
Several research analysts have recently issued reports on the stock. BTIG Research lowered shares of ABIOMED to a “hold” rating in a research note on Wednesday, May 27th. ValuEngine cut ABIOMED from a “buy” rating to a “hold” rating in a report on Thursday, April 2nd. Morgan Stanley raised their price objective on ABIOMED from $149.00 to $152.00 and gave the company an “underweight” rating in a report on Friday, May 1st. SVB Leerink raised their price objective on ABIOMED from $195.00 to $225.00 and gave the company a “market perform” rating in a report on Thursday, May 28th. Finally, Zacks Investment Research cut ABIOMED from a “hold” rating to a “sell” rating and set a $160.00 price objective on the stock. in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. ABIOMED presently has a consensus rating of “Hold” and a consensus price target of $186.40.
ABIOMED (NASDAQ:ABMD) last released its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $0.70 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.26). ABIOMED had a net margin of 24.14% and a return on equity of 18.51%. The business had revenue of $206.66 million during the quarter, compared to analyst estimates of $209.58 million. During the same quarter in the prior year, the company earned $1.60 earnings per share. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. On average, analysts anticipate that ABIOMED, Inc. will post 3.21 earnings per share for the current fiscal year.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Read More: Quick Ratio
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.